pioglitazone has been researched along with Liver Dysfunction in 15 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These beneficial effects of VIT D may expand its use by diabetics combined with antidiabetic drugs due to its anti-inflammatory, antioxidant, and antiapoptotic properties." | 5.72 | Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress. ( Elyamany, MF; Hamouda, HA; Mansour, SM, 2022) |
| "Metformin treatment showed either small mean increases or decreases." | 2.71 | Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. ( Belcher, G; Schernthaner, G, 2005) |
| "Autosomal dominant polycystic kidney disease (ADPKD) is the most common of the monogenic disorders and is characterized by bilateral renal cysts; cysts in other organs including liver, pancreas, spleen, testis and ovary; vascular abnormalities including intracranial aneurysms and subarachnoid hemorrhage; and cardiac disorders such as left ventricular hypertrophy (LVH), mitral valve regurgitation, mitral valve prolapse and aortic regurgitation." | 2.48 | PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. ( Nagao, S; Yamaguchi, T, 2012) |
| "Tamoxifen (TAM) is a chemotherapeutic drug widely utilized to treat breast cancer." | 1.91 | Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1/Nrf2/HO-1 and SIRT1/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis. ( Elariny, HA; Kamel, GAM, 2023) |
| " These beneficial effects of VIT D may expand its use by diabetics combined with antidiabetic drugs due to its anti-inflammatory, antioxidant, and antiapoptotic properties." | 1.72 | Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress. ( Elyamany, MF; Hamouda, HA; Mansour, SM, 2022) |
| "Pioglitazone treatment significantly inhibited hepatic I/R injury as determined by serological and histological analyses." | 1.34 | Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice. ( Akahori, T; Enomoto, K; Hamada, K; Kanehiro, H; Kuzumoto, Y; Nakajima, Y; Nakamura, S; Nomi, T; Sho, M; Suzaki, Y, 2007) |
| "Pioglitazone prevented increase in plasma aspartate transaminase, alanine aminotransferase, and TNF-alpha levels but had no effect on plasma and hepatic levels of lipid peroxide." | 1.32 | Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha. ( Hashimoto, K; Hokkyo, K; Nakajima, H; Ohata, M; Sakamoto, K; Suzuki, H; Toda, G; Yamada, H; Yamauchi, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Pferschy-Wenzig, EM | 1 |
| Atanasov, AG | 1 |
| Malainer, C | 1 |
| Noha, SM | 1 |
| Kunert, O | 1 |
| Schuster, D | 1 |
| Heiss, EH | 1 |
| Oberlies, NH | 1 |
| Wagner, H | 1 |
| Bauer, R | 1 |
| Dirsch, VM | 1 |
| Hamouda, HA | 1 |
| Mansour, SM | 1 |
| Elyamany, MF | 1 |
| Kamel, GAM | 1 |
| Elariny, HA | 1 |
| Dawson, AJ | 1 |
| Kilpatrick, ES | 1 |
| Coady, AM | 1 |
| Elshewehy, AMM | 1 |
| Dakroury, Y | 1 |
| Ahmed, L | 1 |
| Atkin, SL | 1 |
| Sathyapalan, T | 1 |
| Pane, B | 1 |
| Gazzola, V | 1 |
| Spinella, G | 1 |
| Bagnato, P | 1 |
| Grillo, F | 1 |
| Vellone, VG | 1 |
| Palombo, D | 1 |
| Elshazly, S | 1 |
| Soliman, E | 1 |
| Radwan, RR | 1 |
| Hasan, HF | 1 |
| Vuppalanchi, R | 1 |
| Chalasani, N | 1 |
| Aoyama, T | 1 |
| Ikejima, K | 1 |
| Kon, K | 1 |
| Okumura, K | 1 |
| Arai, K | 1 |
| Watanabe, S | 1 |
| Yoshihara, D | 1 |
| Kurahashi, H | 1 |
| Morita, M | 1 |
| Kugita, M | 1 |
| Hiki, Y | 1 |
| Aukema, HM | 1 |
| Yamaguchi, T | 2 |
| Calvet, JP | 1 |
| Wallace, DP | 1 |
| Nagao, S | 2 |
| Ohata, M | 1 |
| Suzuki, H | 1 |
| Sakamoto, K | 1 |
| Hashimoto, K | 1 |
| Nakajima, H | 1 |
| Yamauchi, M | 1 |
| Hokkyo, K | 1 |
| Yamada, H | 1 |
| Toda, G | 1 |
| Belcher, G | 1 |
| Schernthaner, G | 1 |
| Da Silva Morais, A | 1 |
| Abarca-Quinones, J | 1 |
| Horsmans, Y | 1 |
| Stärkel, P | 1 |
| Leclercq, IA | 1 |
| Akahori, T | 1 |
| Sho, M | 1 |
| Hamada, K | 1 |
| Suzaki, Y | 1 |
| Kuzumoto, Y | 1 |
| Nomi, T | 1 |
| Nakamura, S | 1 |
| Enomoto, K | 1 |
| Kanehiro, H | 1 |
| Nakajima, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571] | 1,080 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pioglitazone and Liver Dysfunction
| Article | Year |
|---|---|
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type | 2009 |
PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders.
Topics: Animals; Cardiovascular Diseases; Cell Proliferation; Disease Models, Animal; Fibrosis; Hypoglycemic | 2012 |
2 trials available for pioglitazone and Liver Dysfunction
| Article | Year |
|---|---|
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-C | 2017 |
Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated He | 2005 |
11 other studies available for pioglitazone and Liver Dysfunction
| Article | Year |
|---|---|
Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma.
Topics: Adipocytes; Benzamides; Dose-Response Relationship, Drug; Liver Diseases; Molecular Structure; PPAR | 2014 |
Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Biomarkers; Diabetes Mellitus, Experimental; Diabetes | 2022 |
Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1/Nrf2/HO-1 and SIRT1/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis.
Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Inflammation; Kelch-Like ECH-Associat | 2023 |
Inflammatory Response Modulation through a PPARγ Agonist during Surgically Induced Visceral Ischemia in an Animal Model.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Constriction; Cytoprotection; Disease Models, Animal; Infl | 2018 |
PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/reperfusion injury.
Topics: Acute Kidney Injury; Animals; Caspase 3; Kidney; Liver; Liver Diseases; Male; Pioglitazone; PPAR gam | 2019 |
Pioglitazone ameliorates hepatic damage in irradiated rats
Topics: Animals; Anti-Inflammatory Agents; Fibroblasts; Hypoglycemic Agents; Liver Diseases; Male; Pioglitaz | 2019 |
Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice.
Topics: Adipokines; Animals; Blood Glucose; Diabetes Complications; Hepatectomy; Hypoglycemic Agents; Insuli | 2009 |
PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Topics: Animals; Blood Urea Nitrogen; Cell Proliferation; Disease Models, Animal; Disease Progression; Femal | 2011 |
Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha.
Topics: Animals; Chemical and Drug Induced Liver Injury; Ethanol; Female; Lipopolysaccharides; Liver Disease | 2004 |
Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice.
Topics: Animals; Carbon Tetrachloride; Cells, Cultured; Chemical and Drug Induced Liver Injury; Extracellula | 2007 |
Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice.
Topics: Animals; Apoptosis; Cytokines; Gene Expression Regulation; Hepatocytes; Inflammation; Liver Diseases | 2007 |